Loading clinical trials...
Loading clinical trials...
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Conditions
Interventions
M3814 100 mg
M3814 200 mg
+5 more
Locations
26
United States
Research site
Fresno, California, United States
Holy Cross Hospital Inc.
Fort Lauderdale, Florida, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
Research site
Billings, Montana, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Montefiore Medical Center PRIME
The Bronx, New York, United States
Start Date
September 15, 2015
Primary Completion Date
March 26, 2021
Completion Date
November 19, 2021
Last Updated
October 15, 2024
NCT07403721
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions